Working to deliver
better outcomes with fewer risks
Our vision
Cell therapies have made significant advancements in recent years; however, their broad use is still limited by the risks these treatments can pose. At Orca Bio, we don't accept these limitations—we believe by making cell therapies both safer and more effective, we could push past current boundaries and redefine the future of treatment.
Clinical program
We are currently studying our investigational high-precision cell therapies in several of the most prevalent blood cancers. We are encouraged by our progress and the hope it represents for patients living with serious blood cancers, but these programs are only the beginning.
Our long-term plan is to not only treat serious blood cancers, but develop cell therapies for even more patients who have other blood disorders, solid tumor malignancies, and chronic conditions who could benefit from our platform.
Our pipeline
Orca-T
Orca-T is our lead investigational high-precision cell therapy designed to replace a patient's cancerous blood and immune system with a healthy one while dramatically lowering their risk of developing GvHD and other potentially life-threatening side effects.
In our Phase Ib/II study, when measured against a concurrent, nonrandomized single-center comparator for allogeneic transplant patients, Orca-T demonstrated preliminary evidence of:
- Significantly higher GvHD-free, relapse-free survival rates after 1 year
- Improved relapse-free survival rates
- Lower rates of chronic GvHD
To verify these preliminary results in a larger patient population, Orca-T is being evaluated in a randomized, Phase III pivotal trial.
Orca-Q
While Orca-T requires a fully matched donor, we are also developing Orca-Q, our second investigational high-precision cell therapy candidate designed to deliver therapeutic benefits to patients with haploidentical donors.
Our vision is that Orca-Q could unlock the therapeutic benefits of cell therapy for most patients living with blood cancers who can't find a fully matched donor.
Interim results from the Phase I single-arm, open-label trial showed:
- Reduction of acute grade 2-4 GvHD
- No moderate-to-severe chronic GvHD
- Improved graft-versus-host disease-free, relapse-free survival
This therapy is currently being investigated in an ongoing Phase I trial.
Our publications
We believe in transparency and sharing our findings with the scientific community. To help disseminate our results, we’ve presented our data at multiple national and international congresses.
